{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:51:10Z","timestamp":1777366270129,"version":"3.51.4"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:sec id=\"ab-coi220037-4\"><jats:title>Importance<\/jats:title><jats:p>Treatment options for patients with unresectable and\/or metastatic dedifferentiated liposarcoma (DDLPS) are limited. New drugs are required.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220037-5\"><jats:title>Objective<\/jats:title><jats:p>To assess whether cabazitaxel demonstrated sufficient antitumor activity in patients with metastatic or inoperable locally advanced DDLPS to justify further investigation in a phase 3 setting.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220037-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This international multicenter, open-label single-arm phase 2 trial was conducted at 10 institutions in 4 European countries from March 2015 to March 2019. Eligible patients had to have metastatic or locally advanced histologically proven DDLPS with evidence of disease progression within the past 6 months and had to have received no more than 1 previous line of chemotherapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220037-7\"><jats:title>Interventions<\/jats:title><jats:p>After mandatory central review of tumor blocks, if the DDLPS diagnosis was confirmed, patients started treatment within 72 hours after registration. Cabazitaxel was administered at a dose of 25 mg\/m<jats:sup>2<\/jats:sup> IV infusion over 1 hour every 21 days until intolerance, progression, or withdrawal of consent.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220037-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was progression-free survival (PFS) rate at 12 weeks per RECIST 1.1. Based on a Simon 2-stage design, at least 4 of 17 (stage 1) and 11 of 37 (stage 2) eligible and evaluable patients who were progression free at 12 weeks were needed. The final analysis report was completed on November 17, 2021.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220037-9\"><jats:title>Results<\/jats:title><jats:p>Forty patients were registered, with 2 patients being ineligible. The number of cycles ranged from 1 to 30, with a median of 5; 26 patients (65%) received at least 4 cycles of cabazitaxel. Progression-free survival at 12 weeks was 55%, achieving the primary study end point. At a median follow-up of 21.6 months, median PFS was 6 months and median OS 21 months. Response rate (RR) was 8% with 1 clinical response (CR) and 2 partial responses (PR). Twenty-three (60.5%) patients had a stable disease (SD). Disease control (PR+SD) was achieved in 26 patients (68%).<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220037-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This nonrandomized phase 2 clinical trial met its primary end point, with 21 of 38 patients (55%) being progression free at 12 weeks. These results suggest important activity of cabazitaxel in patients with metastatic or inoperable locally advanced DDLPS. The drug is worth being further studied in these tumors in a phase 3 setting.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.3218","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T16:01:49Z","timestamp":1660924909000},"page":"1420","source":"Crossref","is-referenced-by-count":6,"title":["Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma"],"prefix":"10.1001","volume":"8","author":[{"given":"Roberta","family":"Sanfilippo","sequence":"first","affiliation":[{"name":"Medical Oncology Unit 2, Medical Oncology Dpt, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard L.","family":"Hayward","sequence":"additional","affiliation":[{"name":"Edinburgh Western General Hospital, Edinburgh, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jammbe","family":"Musoro","sequence":"additional","affiliation":[{"name":"EORTC, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Benson","sequence":"additional","affiliation":[{"name":"The Royal Marsden Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Gordon","family":"Leahy","sequence":"additional","affiliation":[{"name":"Christie Hosp NHS Trust, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Brunello","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard, & Univ Claude Bernard Lyon I, Unicancer, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid M. E.","family":"Desar","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasim","family":"Ali","sequence":"additional","affiliation":[{"name":"Clatterbrige Cancer Centre, Wirral, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Hervieu","sequence":"additional","affiliation":[{"name":"Centre Georges-Fran\u00e7ois Leclerc, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khin","family":"Thway","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Marreaud","sequence":"additional","affiliation":[{"name":"EORTC, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Litiere","sequence":"additional","affiliation":[{"name":"EORTC, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Kasper","sequence":"additional","affiliation":[{"name":"Mannheim Cancer Center (MCC), University of Heidelberg, Mannheim University Medical Center, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"11","key":"coi220037r2","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up?.","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"issue":"18","key":"coi220037r3","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1016\/j.ejca.2005.07.023","article-title":"Differential sensitivity of liposarcoma subtypes to chemotherapy.","volume":"41","author":"Jones","year":"2005","journal-title":"Eur J Cancer"},{"issue":"1","key":"coi220037r4","doi-asserted-by":"publisher","first-page":"11836","DOI":"10.1038\/s41598-017-12132-w","article-title":"Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard.","volume":"7","author":"Livingston","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"coi220037r5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial.","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"key":"coi220037r6","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/868973","article-title":"Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma.","volume":"2013","author":"Martin-Liberal","year":"2013","journal-title":"Sarcoma"},{"issue":"1","key":"coi220037r7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2045-3329-4-16","article-title":"High-dose continuous-infusion ifosfamide in advanced well-differentiated\/dedifferentiated liposarcoma.","volume":"4","author":"Sanfilippo","year":"2014","journal-title":"Clin Sarcoma Res"},{"issue":"10028","key":"coi220037r8","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"coi220037r9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13046-021-01886-x","article-title":"Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.","volume":"40","author":"Zuco","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"coi220037r10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01829","article-title":"Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial.","volume":"JCO2101829","author":"Gounder","year":"2022","journal-title":"J Clin Oncol"},{"key":"coi220037r11","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1200\/JCO.2018.36.15_suppl.11514","article-title":"A phase 1 study of MDM2 inhibitor DS-3032b in patients with well\/de-differentiated liposarcoma (WD\/DD LPS), solid tumors (ST) and lymphomas (L).","volume":"36","author":"Bauer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi220037r12","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.","volume":"31","author":"Dickson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi220037r13","doi-asserted-by":"publisher","first-page":"11004","DOI":"10.1200\/JCO.2019.37.15_suppl.11004","article-title":"Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.","volume":"37","author":"Dickson","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi220037r14","doi-asserted-by":"publisher","first-page":"9506","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","article-title":"CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.","volume":"39","author":"Wolchok","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi220037r15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9747","key":"coi220037r16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"coi220037r17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"coi220037r18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"issue":"16","key":"coi220037r19","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1002\/sim.v27:16","article-title":"Proper inference from Simon\u2019s two-stage designs.","volume":"27","author":"Koyama","year":"2008","journal-title":"Stat Med"},{"issue":"6","key":"coi220037r20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3390\/cancers13061453","article-title":"Impact of pathological stratification on the clinical outcomes of advanced well-differentiated\/dedifferentiated liposarcoma treated with trabectedin.","volume":"13","author":"Fabbroni","year":"2021","journal-title":"Cancers (Basel)"},{"key":"coi220037r1","author":"WHO Classification of Tumours Editorial Board","year":"2020"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2795419\/jamaoncology_sanfilippo_2022_oi_220037_1666196322.93913.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T15:06:38Z","timestamp":1666278398000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2795419"}},"subtitle":["A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG)"],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.3218","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}